NPS Pharmaceuticals: The Small Bio-Tech You Should Not Be Ignoring With 30% Upside
- NPS Pharma has two drugs, Gattex and Natpara, with the potential of reaching blockbuster status.
- Natpara is expected to attain FDA approval at the end of FY2014.
- Ability for patients to gain insurance on preexisting conditions will lead to an increase in the overall care of rare, chronic diseases.
- Valuation suggests substantial upside in the 30% range.